Kinfo
Azitra Inc Common Stock logo

Azitra Inc Common Stock

AZTRNYSEHealthcare·US · USD
$0.18
+0.01 (+5.99%)
Close · 2026-06-29

Price

Key statistics

Valuation
Market cap2.70M USD
Enterprise value-7.00M USD
Trailing P/E0.01
Forward P/E-0.32
PEG ratio-0.00
Price / sales0.00
Price / book0.26
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-81.79%
Return on equity-158.71%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-11.66M USD
Net income-11.81M USD
Diluted EPS-$0.95
Rev. growth (YoY)0.00%
Balance sheet
Total cash10.05M USD
Total debt343.33K USD
Debt / equity3.28
Current ratio6.94
Book value / share$0.65
Cash flow (TTM)
Operating cash flow-10.63M USD
Levered free cash flow-6.70M USD
Shares & price
Shares outstanding16.19M
Float12.12M
Held by institutions6.27%
Beta-1.28
50-day MA$0.21
200-day MA$0.34
52-week high$1.83
52-week low$0.10
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-13-0.04-0.25−525.00%2026-03-25-0.530.94+277.36%2026-02-27-0.32-1.17−265.62%2026-02-170.600.69+15.00%2025-11-12-0.77-0.67+12.99%
About Azitra Inc Common Stock

Azitra Inc. is a clinical-stage biotechnology company that focuses on harnessing the therapeutic potential of the human microbiome. The company is dedicated to developing microbiome-based treatments to address dermatological conditions and improve skin health. Azitra leverages its proprietary platform to design therapies that utilize commensal microbiota, which are the naturally occurring bacteria on human skin, for combating various skin diseases. By targeting skin-associated microbiomes, Azitra aims to create safe and effective treatment options for conditions that may not respond well to conventional treatments. Its innovative approach positions Azitra in the emerging field of microbiome therapy, impacting healthcare and dermatology industries. With its specialized focus, Azitra plays a significant role in advancing biotechnology innovations and contributing to the evolving narrative of precision medicine and personalized healthcare.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Francisco D. Salva
Employees
13
Headquarters
Branford, CT, United States

Frequently asked questions about Azitra Inc Common Stock